Antimicrobial Stewardship

The international organization’s first set of guidelines for this serious condition are looking to reduce mortality and morbidity.

A large retrospective cohort study demonstrates greater resistance across different pathogens in this patient population compared with those who do not have cancer.

Jennifer Cohn, MD, MPH, calls for better data, drug access, and care tracking to address gaps in treatment.

WikiGuidelines produces novel clinical practice guidelines developed with pragmatic, applicable methodology, including a diverse author group.

An "alarmingly" wide treatment gap for antimicrobial-resistant infections in under resourced countries is attributed to multiple factors including barriers to access.

De-escalating empiric antimicrobial therapy is a strategy to combat antimicrobial resistance. Antimicrobial stewardship programs can play a major role in preserving antibiotic effectiveness and preventing unnecessary antibiotic use.

Sean Nguyen PharmD, BCIDP, medical director Shionogi, delves into the European cohort portion of the study and offers further information from the trial and some of its bigger clinical ramifications.

The INSPIRE 3 trial demonstrates that computerized order entry recommendation prompts can reduce empiric use of broad-spectrum antibiotics in favor of targeted treatment for skin and soft tissue infections.

From the discovery of penicillin to PK-PD principles: A brief historical overview and what we have learned from recent clinical trials.

A preclinical study shows the antibiotic, piperacillin, was effective at much lower dosages than doxycycline, and did so without disrupting the gut microbiome.

Rifaquizinone is a dual-pharmacophore antibiotic combining rifamycin and a fluoroquinolone-like compound, showing strong bactericidal activity against resistant Staphylococcus aureus strains and biofilms, with promising results for treating prosthetic joint infections (PJI) but limited oral bioavailability.

A recent study evaluated bundled ambulatory stewardship interventions (ASIs) — audits, reporting, webinars, and electronic alerts — to reduce inappropriate antibiotic prescriptions (IAPs) for acute uncomplicated bronchitis (AUB).

A Centers for Disease Control and Prevention study looked at the COVID-19 pandemic's effect on hospital-onset infections. Study lead author Hannah Wolford offers insights on it, including what patient populations were most affected, and the significance of infection prevention strategies.

Global study reveals sharp rise in deaths linked to high-risk antibiotic use, prompting urgent calls for stewardship reform and surveillance improvements globally.

In a phase 3 study, GSK’s gepotidacin demonstrated 92% efficacy against the sexually transmitted infection.

A surge in invasive group A Streptococcal (IGAS) infections in children marked by more virulent strains followed a reduction in cases coinciding with protective measures for the pandemic.

Study shows benefit using antibiotic earlier in clinical care for gram-negative infections.

Although the TB pipeline has several new agents in various phases, challenges to antimicrobial development remain. Therefore treatment adherence remains paramount.

Key updates from the Centers for Disease Control and Prevention on influenza activity, hospitalizations, pediatric deaths, and current trends across the United States.

Patients with suspected sepsis in the emergency department are twice as likely to survive at 28 days when antibiotics are started within 1 hour.

Indwelling devices and previous antibiotic exposure increased the risk for these infections.

The Visby Medical Women’s Sexual Health Test can screen for chlamydia, gonorrhea, and trichomoniasis.

This is the first in a new class of oral antibiotics for uncomplicated urinary tract infections (uUTIs) in nearly 30 years.

Whitney Hartlage, PharmD, explores the role of expanded UTI definitions and urinalysis interpretation in addressing antibiotic overuse.

A long-term study conducted by the Centers for Disease Control and Prevention (CDC) shows early success in the reduction of such infections followed by an increase again during the early pandemic years. Additionally, certain pathogens overall saw an increase, whereas other infections were stable or saw decreases.

The latest Bench to Bedside column reviews new guidance on the treatment of drug-susceptible and drug-resistance Mycobacterium tuberculosis infections.

A machine learning assessment agrees with an evaluation based on factors identified by infectious diseases experts that IDSA guidelines for treating uncomplicated UTI, last issued in 2011, remain valid today.

This week, phage and antibiotic treatment for resistant Pseudomonas infections, concerns over SEP-1’s impact on sepsis management, and ongoing measles outbreak signaling declining vaccination rates.